Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089790 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
A Phase 3 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
NCT01089790 is a Phase 3 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 141 participants.
The verdict
NCT01089790, a Phase 3 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Sitagliptin
- DRUG Dutogliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089790
The ClinicalTrials.gov registry entry for NCT01089790 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sitagliptin is the first listed.
NCT01089790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01089790 about?
NCT01089790 is a clinical study titled "Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone". This study will evaluate the long-term safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01089790?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2010-03.
What interventions are being tested in trial NCT01089790?
The interventions under investigation include: Sitagliptin (DRUG), Dutogliptin (DRUG).
Who is sponsoring clinical trial NCT01089790?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.